Revolutionary gene-editing technique to stop AIDS virus in its tracks

September 24, 2015 by Keyonna Summers, University of Nevada, Las Vegas
UNLV professor Marty Schiller working in his lab. Credit: R. Marsh Starks/UNLV Photo Services

Researchers with the Nevada Institute of Personalized Medicine at UNLV have engineered a new protein that they believe has placed science much closer to an HIV cure.

A patent application has been filed and testing is underway on the protein—called HT-TALENs (short for HIV-targeted transcription activator-like effector nucleases)—which uses a newly developed gene-editing technique to rid the body's cells of the immunodeficiency virus before it has a chance to multiply and possibly develop into AIDS. Here's how it works:

Humans infected with HIV have 1 million to 10 million cells harboring copies of HIV DNA. When HIV infects someone, the virus inserts itself into DNA cells and becomes part of those cells' permanent blueprint.

"Current drugs slow the virus from being produced, but they don't rid the body of the HIV DNA," said NIPM executive director and UNLV professor Marty Schiller. "You've got to get rid of or damage the harmful DNA to truly prevent the cells from creating the virus."

By altering a commonly used plant protein, Schiller's lab engineered the new HT-TALENs variation. Introduced into the body through a injection, the protein adheres to the specific portions of DNA laden with HIV and acts as a pair of scissors that cuts or damages it without touching any of the non-infected DNA around it. When the cell repairs itself, the new copy won't contain functional HIV.

"This is a way we're getting at the root cause of AIDS—not going after a downstream event, but going after the actual DNA copy—and hopefully stopping virus replication in its tracks," Schiller said. "We think it has the potential to be a cure."

So far, the researchers have only produced results in petri dishes. They are awaiting patent approval and are gearing up to start on the next phase of testing this winter through a partnership with Brigham Young University. If that's successful, the scientists will move on to human trials.

Time frame for market use? Schiller hates to speculate, but if all goes well the best-case scenario is seven years.

"It's going to take a number of years to develop, but I'm pretty sure this approach should work and our goal is to lead the way," he said.

The protein treatment's success would be a boon emotionally and financially for patients undergoing current HIV drug regimens, which can top $15,000 a year.

Human tests would pair the new gene-editing protein therapy with current treatments. The protein might also be useful in curing other illnesses like bird flu.

The approach is revolutionary, Schiller said, considering that genetics—now widely used for prenatal screening and drug development—seemed a mere fantasy when referenced in the 1993 film Jurassic Park.

This project—one of about eight Schiller's lab is currently working on—began about three years ago after a weekly meeting of Schiller's team focused on current research papers. Schiller realized that the TALEN , derived from a wheat pathogen already widely used in the agriculture industry to genetically modify plants, described in one paper might be perfect after a few tweaks for use in HIV therapy.

The findings were published in the May issue of the peer-reviewed journal PLoS ONE.

Researchers included students with post-doctoral, graduate, and undergraduate status, and even some assistance by a local high school junior. Schiller said co-authorship in a major publication, especially on a project of this magnitude, is a major coup for young researchers. In fact, co-lead author Christy Strong, a former post-doctoral student, has since become a UNLV professor. The project inspired the other lead author, undergraduate Horacio Guerra, to switch career paths. He changed majors from a pre-med track to focus on scientific research. He graduated in the spring from UNLV with a bachelor of science in biology and is now in the graduate program at University of California, San Diego.

Explore further: Cancer drug promises to break down barrier to HIV cure

More information: "Damaging the Integrated HIV Proviral DNA with TALENs." PLoS ONE 10(5): e0125652. DOI: 10.1371/journal.pone.0125652

Related Stories

Cancer drug promises to break down barrier to HIV cure

September 18, 2015
Researchers have found a promising way of kicking the AIDS virus out of its hiding place in infected cells, potentially removing the main obstacle to curing HIV.

HIV grows despite treatment, study finds

August 4, 2015
HIV can continue to grow in patients who are thought to be responding well to treatment, according to research by the University of Liverpool.

Scientists reawaken sleeping HIV in patient cells to eliminate the virus

September 9, 2015
A consortium of investigators led by scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have found that a new class of drugs may be used to purge pockets of dormant HIV from a patient's body, eliminating ...

Identification of drug combinations that reverse HIV-1 latency

March 30, 2015
There are almost 40 million people throughout the world living with HIV-1/AIDs. While current antiretroviral therapies are able to reduce the amount of virus in the blood, HIV remains present in a latent state within T cells. ...

Editing HIV out of our genome with CRISPR

April 9, 2015
The virus that causes AIDS is an efficient and crafty retrovirus. Once HIV inserts its DNA into the genome of its host cells, it has a long incubation period, and can remain dormant and hidden for years. And while physicians ...

Stem cell gene therapy holds promise for eliminating HIV infection

July 1, 2015
cientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are one step closer to engineering a tool that could one day arm the body's immune system to fight HIV—and win. The new technique ...

Recommended for you

New HIV therapy reduces virus, boosts immunity in drug-resistant patients

August 15, 2018
In a study, a new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy ...

In choosing care, HIV patients in Zambia prefer kindness over convenience

August 15, 2018
As a healthcare patient, what would you sacrifice for a provider with a nice—rather than rude—attitude? For HIV patients in Zambia, the answer may surprise you.

Details of HIV-1 structure open door for potential therapies

August 9, 2018
New research provides details of how the structure of the HIV-1 virus is assembled, findings that offer potential new targets for treatment.

Researchers uncover potential new drug targets in the fight against HIV

August 7, 2018
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that ...

Naltrexone helps HIV positive individuals reduce heavy alcohol use

August 7, 2018
Extended-release naltrexone—an injection that decreases heavy drinking in the general population when taken in conjunction with counseling—appears to help HIV-positive individuals reduce their number of heavy drinking ...

EU door opens for generic version of AIDS medicine Truvada

July 26, 2018
Patient associations on Thursday lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.